Square Pharmaceuticals PLC has declared a 120 percent cash dividend for the financial year ending June 30, 2025, as approved by its board of directors at a meeting on Wednesday. The leading drug manufacturer paid a 100 percent cash dividend for the previous year.
According to the company’s financial statement, consolidated earnings per share (EPS) increased by 15 percent to Tk 27.04 in 2024–25 from Tk 23.61 a year earlier, while standalone EPS rose by 26 percent to Tk 20.90 from Tk 16.63.
Consolidated results represent the combined financial performance of Square Pharma and its subsidiaries, whereas standalone figures reflect only the company’s core operations.
Consolidated net asset value (NAV) per share rose by 11 percent to Tk 157.88 from Tk 142.05, while standalone NAV per share increased by 4 percent to Tk 124.71 from Tk 119.35. Net operating cash flow per share rose by 9 percent to Tk 19.52 on a consolidated basis from Tk 17.96 and to Tk 19.96 on a standalone basis from Tk 17.59.
The company said its 59th Annual General Meeting will be held virtually on December 15, with November 16 set as the record date.
The Board also approved Tk 650 crore for balancing, modernisation, rehabilitation and expansion (BMRE), capital machineries, and land acquisition to support future growth.
Square Pharma shares closed unchanged at Tk 213 on the Dhaka Stock Exchange on Wednesday.
